← Leaderboards
Ayman Al-Hendy
University Of Texas Medical Br Galveston
$16,587,078
Attributed
$23,069,178
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,460,298 · 14
By mechanism
R01$17,156,549 · 5
U54$4,591,120 · 3
G12$1,242,616 · 3
R21$368,935 · 1
P20$101,078 · 2
Top collaborators
- Thomas G Boyer13 shared
- Cheryl L Walker9 shared
- Frank J Gonzalez6 shared
- Qiwei Yang2 shared
- James E.K Hildreth1 shared
Most similar at University Of Texas Medical Br Galveston
Same institution · by research overlap
- E Aubrey Thompson$2,793,172
Others in their field
Top investigators on “S Health”
- David Heimbrook · Leidos Biomedical Research, Inc.$990,124,787
- Leonard Freedman · Leidos Biomedical Research, Inc.$886,472,023
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Lawrence Corey · Fred Hutchinson Cancer Center$584,604,175
- Bambra Strokes · Ppd Development Lp$526,656,217
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$518,533,320
Research focus
S HealthWomen&AposUterine FibroidsWomanLeiomyomaMyometriumFibroid TumorTumorPathogenesisNeoplasticGenetic TranscriptionSafetySignal TransductionAnimal ModelResponseAfrican AmericanMedicalAffectBenignLinkPathway InteractionsEtiologyGenesCells
Grant awards (52)
Pathological reprogramming of the m6A epitranscriptome in uterine fibroids$647,762
R01 · FY2025 · HD
Pathological reprogramming of the m6A epitranscriptome in uterine fibroids$641,284
R01 · FY2024 · HD
Pathological reprogramming of the m6A epitranscriptome in uterine fibroids$647,762
R01 · FY2023 · HD
3/4, University of Illinois at Chicago Clinical Site- Reproductive Medicine Collaborative Consortium: A randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids$311,640
R01 · FY2023 · HD
Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroids$750,924
R01 · FY2022 · HD
Pathological reprogramming of the m6A epitranscriptome in uterine fibroids$647,762
R01 · FY2022 · HD
Investigating the effectiveness of COVID-19 testing choices, community engagement, and culturally-embedded mHealth literacy delivery in a medically-underserved, community-based sample$475,882
R01 · FY2022 · ES · contact PI
3/4, University of Illinois at Chicago Clinical Site- Reproductive Medicine Collaborative Consortium: A randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids$311,640
R01 · FY2022 · HD
Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroids$86,045
R01 · FY2022 · HD
Investigating the effectiveness of COVID-19 testing choices, community engagement, and culturally-embedded mHealth literacy delivery in a medically-underserved, community-based sample$1,609,765
R01 · FY2021 · ES · contact PI
Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroids$750,924
R01 · FY2021 · HD
Pathological reprogramming of the m6A epitranscriptome in uterine fibroids$661,325
R01 · FY2021 · HD
Gene X Environment Interactions in the Pathogenesis of Uterine Fibroids$521,275
R01 · FY2021 · ES · contact PI
3/4, University of Illinois at Chicago Clinical Site- Reproductive Medicine Collaborative Consortium: A randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids$311,640
R01 · FY2021 · HD
Community-Engaged Covid-19 Interventions to Protect and Monitor Children$300,000
R01 · FY2021 · ES · contact PI
Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroids$88,214
R01 · FY2021 · HD
Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroids$764,686
R01 · FY2020 · HD
Gene X Environment Interactions in the Pathogenesis of Uterine Fibroids$355,868
R01 · FY2020 · ES · contact PI
3/4, University of Illinois at Chicago Clinical Site- Reproductive Medicine Collaborative Consortium: A randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids$318,001
R01 · FY2020 · HD
Implications of MTHFR Polymorphisms in Women receiving a Combination of Green Tea Extract and Fertility Promoting Drugs on Serum Folate Levels$159,900
R01 · FY2020 · HD
Gene X Environment Interactions in the Pathogenesis of Uterine Fibroids$152,953
R01 · FY2020 · ES · contact PI
Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroids$762,498
R01 · FY2019 · HD
Gene X Environment Interactions in the Pathogenesis of Uterine Fibroids$507,986
R01 · FY2019 · ES · contact PI
3/4, University of Illinois at Chicago Clinical Site- Reproductive Medicine Collaborative Consortium: A randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids$318,001
R01 · FY2019 · HD
Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroids$236,985
R01 · FY2019 · HD
Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroids$775,102
R01 · FY2018 · HD
Gene X Environment Interactions in the Pathogenesis of Uterine Fibroids$522,961
R01 · FY2018 · ES · contact PI
Gene X Environment Interactions in the Pathogenesis of Uterine Fibroids$377,894
R01 · FY2017 · ES · contact PI
Gene X Environment Interactions in the Pathogenesis of Uterine Fibroids$127,605
R01 · FY2017 · ES · contact PI
Targeting Adenovirus for Gene Therapy of Uterine Leiomyoma$336,124
R01 · FY2014 · HD · contact PI
Targeting Adenovirus for Gene Therapy of Uterine Leiomyoma$271,930
R01 · FY2013 · HD · contact PI
Targeting Adenovirus for Gene Therapy of Uterine Leiomyoma$283,647
R01 · FY2012 · HD · contact PI
Targeting Adenovirus for Gene Therapy of Uterine Leiomyoma$285,104
R01 · FY2011 · HD · contact PI
Targeting Adenovirus for Gene Therapy of Uterine Leiomyoma$63,453
R01 · FY2011 · HD · contact PI
CENTER FOR WOMEN'S HEALTH RESEARCH FACULTY RECRUITMENT$464,103
G12 · FY2010 · RR · contact PI
Targeting Adenovirus for Gene Therapy of Uterine Leiomyoma$310,086
R01 · FY2010 · HD · contact PI
MEHARRY CLINICAL AND TRANSLATIONAL RESEARCH CENTER (METRC)$2,814,000
U54 · FY2009 · RR · contact PI
MEHARRY CLINICAL AND TRANSLATIONAL RESEARCH CENTER (METRC)$1,386,000
U54 · FY2009 · RR · contact PI
Meharry Clinical and Translational Research Center (MeTRC)$391,120
U54 · FY2009 · RR · contact PI
CENTER FOR WOMEN'S HEALTH RESEARCH FACULTY RECRUITMENT$265,127
G12 · FY2009 · RR · contact PI
EFFECT OF ORAL CONTRACEPTIVES AND ENDGENOUS SEX STEROIDS ON UTERINE LEIOMYOMAS$14,440
P20 · FY2009 · RR · contact PI
CENTER FOR WOMEN'S HEALTH RESEARCH FACULTY RECRUITMENT$513,386
G12 · FY2008 · RR · contact PI
EFFECT OF ORAL CONTRACEPTIVES AND ENDGENOUS SEX STEROIDS ON UTERINE LEIOMYOMAS$86,638
P20 · FY2008 · RR · contact PI
Estrogen Dependency of Uterine Leiomyoma$236,130
R01 · FY2007 · HD · contact PI
Estrogen Dependency of Uterine Leiomyoma$37,446
R01 · FY2007 · HD · contact PI
Estrogen Dependency of Uterine Leiomyoma$288,806
R01 · FY2006 · HD · contact PI
Reversal of Infertility in Ovarian Failure$199,060
R21 · FY2006 · HD · contact PI
Estrogen Dependency of Uterine Leiomyoma$293,814
R01 · FY2005 · HD
Reversal of Infertility in Ovarian Failure$169,875
R21 · FY2005 · HD
Estrogen Dependency of Uterine Leiomyoma$4,639
R01 · FY2005 · HD
Estrogen Dependency of Uterine Leiomyoma$299,086
R01 · FY2004 · HD
Estrogen Dependency of Uterine Leiomyoma$302,000
R01 · FY2003 · HD